Efficacy and safety of calcineurin inhibitors use in patients with systemic lupus erythematosus

Systemic lupus erythematosus is a complex autoimmune disease in which more than one-third of patients develop lupus nephritis (LN), leading to chronic kidney disease and end-stage renal failure. The treatment of LN has always been a challenge. Tacrolimus is an effective immunosuppressant that has be...

Full description

Saved in:
Bibliographic Details
Main Authors: N. Yu. Nikishina, E. A. Aseeva, S. K. Soloviev, A. M. Lila, A. V. Datcina, E. T. Pletnev
Format: Article
Language:Russian
Published: IMA-PRESS LLC 2025-06-01
Series:Современная ревматология
Subjects:
Online Access:https://mrj.ima-press.net/mrj/article/view/1784
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849242046397677568
author N. Yu. Nikishina
E. A. Aseeva
S. K. Soloviev
A. M. Lila
A. V. Datcina
E. T. Pletnev
author_facet N. Yu. Nikishina
E. A. Aseeva
S. K. Soloviev
A. M. Lila
A. V. Datcina
E. T. Pletnev
author_sort N. Yu. Nikishina
collection DOAJ
description Systemic lupus erythematosus is a complex autoimmune disease in which more than one-third of patients develop lupus nephritis (LN), leading to chronic kidney disease and end-stage renal failure. The treatment of LN has always been a challenge. Tacrolimus is an effective immunosuppressant that has been increasingly used in recent years for the treatment of LN.
format Article
id doaj-art-5508789c7fcd41c5adb1aba20b8271f7
institution Kabale University
issn 1996-7012
2310-158X
language Russian
publishDate 2025-06-01
publisher IMA-PRESS LLC
record_format Article
series Современная ревматология
spelling doaj-art-5508789c7fcd41c5adb1aba20b8271f72025-08-20T03:59:56ZrusIMA-PRESS LLCСовременная ревматология1996-70122310-158X2025-06-0119311512010.14412/1996-7012-2025-3-115-1202800Efficacy and safety of calcineurin inhibitors use in patients with systemic lupus erythematosusN. Yu. Nikishina0E. A. Aseeva1S. K. Soloviev2A. M. Lila3A. V. Datcina4E. T. Pletnev5V.A. Nasonova Research Institute of RheumatologyV.A. Nasonova Research Institute of RheumatologyV.A. Nasonova Research Institute of RheumatologyV.A. Nasonova Research Institute of Rheumatology ; Department of Rheumatology, Russian Medical Academy of Continuing Professional Education, Ministry of Health of RussiaV.A. Nasonova Research Institute of RheumatologyV.A. Nasonova Research Institute of RheumatologySystemic lupus erythematosus is a complex autoimmune disease in which more than one-third of patients develop lupus nephritis (LN), leading to chronic kidney disease and end-stage renal failure. The treatment of LN has always been a challenge. Tacrolimus is an effective immunosuppressant that has been increasingly used in recent years for the treatment of LN.https://mrj.ima-press.net/mrj/article/view/1784systemic lupus erythematosuslupus nephritiscalcineurin inhibitors
spellingShingle N. Yu. Nikishina
E. A. Aseeva
S. K. Soloviev
A. M. Lila
A. V. Datcina
E. T. Pletnev
Efficacy and safety of calcineurin inhibitors use in patients with systemic lupus erythematosus
Современная ревматология
systemic lupus erythematosus
lupus nephritis
calcineurin inhibitors
title Efficacy and safety of calcineurin inhibitors use in patients with systemic lupus erythematosus
title_full Efficacy and safety of calcineurin inhibitors use in patients with systemic lupus erythematosus
title_fullStr Efficacy and safety of calcineurin inhibitors use in patients with systemic lupus erythematosus
title_full_unstemmed Efficacy and safety of calcineurin inhibitors use in patients with systemic lupus erythematosus
title_short Efficacy and safety of calcineurin inhibitors use in patients with systemic lupus erythematosus
title_sort efficacy and safety of calcineurin inhibitors use in patients with systemic lupus erythematosus
topic systemic lupus erythematosus
lupus nephritis
calcineurin inhibitors
url https://mrj.ima-press.net/mrj/article/view/1784
work_keys_str_mv AT nyunikishina efficacyandsafetyofcalcineurininhibitorsuseinpatientswithsystemiclupuserythematosus
AT eaaseeva efficacyandsafetyofcalcineurininhibitorsuseinpatientswithsystemiclupuserythematosus
AT sksoloviev efficacyandsafetyofcalcineurininhibitorsuseinpatientswithsystemiclupuserythematosus
AT amlila efficacyandsafetyofcalcineurininhibitorsuseinpatientswithsystemiclupuserythematosus
AT avdatcina efficacyandsafetyofcalcineurininhibitorsuseinpatientswithsystemiclupuserythematosus
AT etpletnev efficacyandsafetyofcalcineurininhibitorsuseinpatientswithsystemiclupuserythematosus